The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
2-cyclopropyl-N-(4-(4,4-difluoropiperidin-1-yl)pyridin-3-yl)imidazo[1,2-b]pyridazine-8-carboxamide ID: ALA5282376
Max Phase: Preclinical
Molecular Formula: C20H20F2N6O
Molecular Weight: 398.42
Associated Items:
Names and Identifiers Canonical SMILES: O=C(Nc1cnccc1N1CCC(F)(F)CC1)c1ccnn2cc(C3CC3)nc12
Standard InChI: InChI=1S/C20H20F2N6O/c21-20(22)5-9-27(10-6-20)17-4-7-23-11-15(17)26-19(29)14-3-8-24-28-12-16(13-1-2-13)25-18(14)28/h3-4,7-8,11-13H,1-2,5-6,9-10H2,(H,26,29)
Standard InChI Key: PYDXUBHPYGQXBU-UHFFFAOYSA-N
Molfile:
RDKit 2D
29 33 0 0 0 0 0 0 0 0999 V2000
-3.6461 -0.5146 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
-3.2600 0.2144 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-4.0750 0.2144 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
-2.4879 -0.2144 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.7587 0.2144 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.7587 1.0723 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-2.4879 1.5013 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.2600 1.0723 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.0295 1.5013 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.3002 1.0723 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.3002 0.2144 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
0.4288 -0.2144 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.1580 0.2144 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
0.4288 -1.0723 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.3002 -1.5013 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.3002 -2.3163 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.4288 -2.7452 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
1.1580 -2.3163 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
1.9730 -2.5737 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.4879 -1.8873 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.9730 -1.2010 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
1.1580 -1.5013 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.3457 -1.8873 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.0750 -1.5013 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.0750 -2.3163 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.4288 1.5013 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.4288 2.3592 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-0.3002 2.7452 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.0295 2.3592 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1 2 1 0
2 3 1 0
2 4 1 0
4 5 1 0
5 6 1 0
6 7 1 0
7 8 1 0
2 8 1 0
6 9 1 0
9 10 2 0
10 11 1 0
11 12 1 0
12 13 2 0
12 14 1 0
14 15 2 0
15 16 1 0
16 17 2 0
17 18 1 0
18 19 1 0
19 20 2 0
20 21 1 0
21 22 2 0
14 22 1 0
18 22 1 0
20 23 1 0
23 24 1 0
24 25 1 0
23 25 1 0
10 26 1 0
26 27 2 0
27 28 1 0
28 29 2 0
9 29 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Topical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 398.42Molecular Weight (Monoisotopic): 398.1667AlogP: 3.49#Rotatable Bonds: 4Polar Surface Area: 75.42Molecular Species: NEUTRALHBA: 6HBD: 1#RO5 Violations: ┄HBA (Lipinski): 7HBD (Lipinski): 1#RO5 Violations (Lipinski): ┄CX Acidic pKa: ┄CX Basic pKa: 8.02CX LogP: 2.62CX LogD: 2.06Aromatic Rings: 3Heavy Atoms: 29QED Weighted: 0.73Np Likeness Score: -1.53
References 1. Hartz RA, Ahuja VT, Sivaprakasam P, Xiao H, Krause CM, Clarke WJ, Kish K, Lewis H, Szapiel N, Ravirala R, Mutalik S, Nakmode D, Shah D, Burton CR, Macor JE, Dubowchik GM.. (2023) Design, Structure-Activity Relationships, and In Vivo Evaluation of Potent and Brain-Penetrant Imidazo[1,2-b ]pyridazines as Glycogen Synthase Kinase-3β (GSK-3β) Inhibitors., 66 (6): [PMID:36950863 ] [10.1021/acs.jmedchem.3c00133 ]